(-)-α-Pinene

Research use only, not for human use.

(1S)-(-)-Alpha-Pinene enhances the quantity of NREMS without affecting the intensity of NREMS by prolonging GABAergic synaptic transmission, acting as a partial modulator of GABAA-BZD receptors and directly binding to the BZD binding site of GABAA receptor.

(1S)-(-)-Alpha-Pinene enhances the quantity of NREMS without affecting the intensity of NREMS by prolonging GABAergic synaptic transmission, acting as a partial modulator of GABAA-BZD receptors and directly binding to the BZD binding site of GABAA receptor.(In Vitro):(1S)-(-)-Alpha-Pinene significantly increased the duration of non-rapid eye movement sleep (NREMS) and reduced the sleep latency by oral administration without affecting duration of rapid eye movement sleep and delta activity. (1S)-(-)-Alpha-Pinene potentiated the GABAA receptor-mediated synaptic response by increasing the decay time constant of sIPSCs in hippocampal CA1 pyramidal neurons. These effects of (1S)-(-)-Alpha-Pinene on sleep and inhibitory synaptic response were mimicked by zolpidem, acting as a modulator for GABAA-BZD receptors, and fully antagonized by flumazenil, an antagonist for GABAA-BZD receptor. (1S)-(-)-Alpha-Pinene was found to bind to aromatic residues of α1- and -γ2 subunits of GABAA-BZD receptors in the molecular model.

(-)-α-pinene enhances the quantity of non-rapid eye movement sleep (NREMS) without affecting the intensity of NREMS by prolonging GABAergic synaptic transmission, acting as a partial modulator of GABAA-BZD receptors and directly binding to the BZD binding site of GABAA receptor.

——

(1S)-(-)-Alpha-Pinene

Others

Other Targets

——

——

——

7785-26-4

136.238

C10H16

>98% (HPLC)

In Vitro:?DMSO : 60 mg/mL (440.43 mM)

CC1=CC[C@H]2C[C@@H]1C2(C)C

——

(-20℃)

With Ice Pack

≥ 2 years